Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast Conserving Therapy
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer, Other Indications |
| Therapuetic Areas: | Oncology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/23/2019 |
| Start Date: | June 2014 |
| End Date: | December 2020 |
Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast
This study is a single-centered, double-blind, two-arm randomized study to determine if oral
glutamine will reduce radiation toxicity for the subjects undergoing Breast Conserving
Therapy.
glutamine will reduce radiation toxicity for the subjects undergoing Breast Conserving
Therapy.
Inclusion Criteria:
- Subject have been diagnosed with Stage I or II invasive breast cancer
- Subject will undergo Accelerated Partial Breast Irradiation (APBI) as part of Breast
Conserving Therapy (BCT)
- Subject is eligible for APBI based on American Society of Therapeutic Radiation
Oncology (ASTRO) criteria
- Subject is 18 years of age or older
- Subject is female
Exclusion Criteria:
- History of uncontrolled, clinically significant lung, heart, endocrine, liver, or
renal disease
- Subject has been diagnosed with any other cancer
- Subject has a known hypersensitivity reaction to the following: oral glutamine (GLN),
glutamate, monosodium glutamate (MSG) (i.e., Chinese restaurant syndrome)
- Subject has history of collagen vascular disease
- Subject has been diagnosed with Diabetes mellitus I or II
- Subject has had any prior breast radiation
- Subject is pregnant or breastfeeding
We found this trial at
1
site
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Loverd Peacock, MD
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
